Turning Point Therapeutics has long set a clear goal to shoot for an accelerated approval of repotrectinib, its tyrosine kinase inhibitor for ROS1- or NTRK-driven tumors. Now armed with positive, if preliminary, Phase II data, the biotech said they may be FDA-ready even sooner than expected.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,